FDA Approves Imfinzi (durvalumab) as First-Line Therapy for Limited-Stage SCLC
On December 4, 2024, the U.S. Food and Drug Administration (FDA) approved the use of (durvalumab) for adults with limited-stage small cell lung cancer...
On December 4, 2024, the U.S. Food and Drug Administration (FDA) approved the us...
